Publicly-Traded Addiction Treatment Co. Signs Exclusive Licensing Agreement With Alar Pharmaceuticals
Addiction treatment company Indivior PLC (NASDAQ: INDV) obtained exclusive global rights to develop, produce and commercialize Alar Pharmaceuticals’ portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting
